{"id":1171,"date":"2019-12-05T12:11:27","date_gmt":"2019-12-05T12:11:27","guid":{"rendered":"https:\/\/medxelerator.com\/?p=1171"},"modified":"2019-12-05T12:28:01","modified_gmt":"2019-12-05T12:28:01","slug":"append-medical-selected-to-present-first-of-its-kind-no-implant-stroke-risk-reduction-device-at-ici-meeting-2019","status":"publish","type":"post","link":"https:\/\/medxelerator.com\/append-medical-selected-to-present-first-of-its-kind-no-implant-stroke-risk-reduction-device-at-ici-meeting-2019\/","title":{"rendered":"Append Medical Selected to Present First-Of-Its-Kind, No-Implant Stroke Risk Reduction Device at ICI Meeting 2019"},"content":{"rendered":"
<\/p>\n
Append Medical Selected to Present First-Of-Its-Kind, No-Implant Stroke Risk Reduction Device at ICI Meeting 2019<\/strong><\/p>\n Append Medical\u2019s Novel Approach to Left Atrial Appendage (LAA) Closure to be Featured at International Conference for Innovations in Cardiovascular Interventions<\/em><\/p>\n OR YEHUDA, Israel \u2013December 5, 2019 — Append Medical<\/a>, developer of a novel LAA closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition.<\/p>\n Append Medical will also present in the Digital Presentations: Complex Coronary and Valvular Interventions program during the meeting. The LAA closure market is the second-fastest growing segment of the medical device market, estimated to reach $958 million by 2025, according to Energias Market Research<\/a>.<\/p>\n The company operates as part of MEDX Xelerator in Israel. MEDX Xelerator\u2019s partners include MEDX Ventures, Boston Scientific Inc., Intellectual Ventures and Sheba Medical Center. ###<\/p>\n About Append Medical<\/strong>
\nOriginally conceived by Professor Leonid Sternik, MD, Director of the Department of Cardiac Surgery at Sheba Medical Center, the Append Medical \u201cAppligator™\u201d device is designed to reduce stroke risk in AF patients by completely closing the LAA to prevent blood clot leakage. Its design is intended to minimize device-related thromboembolism risk by leaving only a suture \u2013 and no metal \u2013 at the closure site.<\/p>\n
\nFor more information on the 2019 ICI Meeting, and the Global Innovation Award Competition, please visit https:\/\/icimeeting.com\/<\/a>.<\/p>\n
\nFounded in 2017, Append Medical is the developer of a patented No-Implant Left Atrial Appendage (LAA) closure solution. The Appligator™ is designed to achieve full closure of the LAA to reduce stroke risk in patients with non-valvular atrial fibrillation. Append Medical is a privately held company operating as part of MEDX Xelerator in Israel. Its major shareholders are MEDX Ventures, Boston Scientific Inc, Intellectual Ventures and the company\u2019s founders.<\/p>\n